Business
Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
- Topline data from proof-of-concept study of VRDN-001 in patients with chronic thyroid eye disease (TED) are expected in June/July 2023 - - Selection of lead
About this update from Viridian Therapeutics, Inc.
[{"type":"text","content":"- Topline data from proof-of-concept study of VRDN-001 in patients with chronic thyroid eye disease (TED) are expected in June/July 2023 - - Selection of lead subcutaneous (SC) program in TED planned for year-end 2023 - - Company adds multiple senior executives to its leadership team, including its first Chief Commercial Officer, as part of its ongoing growth - - Conference call today at 4:30pm ET - WALTHAM, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced financial results and provided a corporate update for the first quarter ended March 31, 2023. “This is an important year for Viridian as we prepare to report topline data from our proof-of-concept study examining VRDN-001 in patients with chronic TED, and later this year, initiate our THRIVE-2 Phase 3 trial, select our lead SC program, and disclose details of at least one of our preclinical programs,” said Scott Myers, President and CEO of Viridian Therapeutics. “We began 2023 building significant momentum with the VRDN-001 low dose data update in patients with active TED. We added several senior executives to our leadership team, marking a critical step in our mission to deliver potential best-in-class medicines for patients and becoming a fully integrated biopharmaceutical company.” Program highlights Thyroid eye disease (TED) Intravenous (IV) program: VRDN-001Viridian’s lead product candidate, VRDN-001, is a monoclonal antibody which acts as a full antagonist of insulin-like growth factor-1 receptor (IGF-1R). VRDN-001 is being evaluated in clinical trials for the treatment of active and chronic TED. Data from the Phase 1/2 clinical trial of VRDN-001 in patients with active TED were highlighted in an oral presentation at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO 2023) in April.The VRDN-001 proof-of-concept study in patients with chronic TED is fully enrolled, with topline data from the 10 mg/kg and 3 mg/kg dose cohorts expected in June or July 2023.Initiation of the THRIVE-2 Phase 3 trial evaluating the efficacy and safety of VRDN-001 in patients with chronic TED is planned for the middle of 2023, with topline results expected by year-end 2024. The THRIVE Ph...